Jon Congleton's most recent trade in Mineralys Therapeutics Inc was a trade of 9,119 Common Stock done at an average price of $32.2 . Disclosure was reported to the exchange on Jan. 12, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Mineralys Therapeutics Inc | Jon Congleton | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 32.21 per share. | 12 Jan 2026 | 9,119 | 646,268 | - | 32.2 | 293,707 | Common Stock |
| Mineralys Therapeutics Inc | Jon Congleton | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 33.15 per share. | 12 Jan 2026 | 7,117 | 639,151 | - | 33.2 | 235,932 | Common Stock |
| Mineralys Therapeutics Inc | Jon Congleton | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2025 | 24,082 | 0 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | Jon Congleton | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 21 Nov 2025 | 24,082 | 655,387 | - | 0.5 | 13,004 | Common Stock |
| Mineralys Therapeutics Inc | Jon Congleton | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 45.83 per share. | 11 Nov 2025 | 112,275 | 664,155 | - | 45.8 | 5,145,956 | Common Stock |
| Mineralys Therapeutics Inc | Jon Congleton | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 46.89 per share. | 11 Nov 2025 | 32,850 | 631,305 | - | 46.9 | 1,540,212 | Common Stock |
| Mineralys Therapeutics Inc | Jon Congleton | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 45.20 per share. | 11 Nov 2025 | 29,207 | 776,430 | - | 45.2 | 1,320,165 | Common Stock |
| Mineralys Therapeutics Inc | Jon Congleton | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 41.64 per share. | 11 Nov 2025 | 12,806 | 818,499 | - | 41.6 | 533,235 | Common Stock |
| Mineralys Therapeutics Inc | Jon Congleton | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 42.31 per share. | 11 Nov 2025 | 8,862 | 809,637 | - | 42.3 | 374,947 | Common Stock |
| Mineralys Therapeutics Inc | Jon Congleton | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 43.50 per share. | 11 Nov 2025 | 4,000 | 805,637 | - | 43.5 | 173,984 | Common Stock |
| Mineralys Therapeutics Inc | Jon Congleton | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 42.63 per share. | 13 Oct 2025 | 13,548 | 832,857 | - | 42.6 | 577,544 | Common Stock |
| Mineralys Therapeutics Inc | Jon Congleton | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 43.03 per share. | 13 Oct 2025 | 1,552 | 831,305 | - | 43.0 | 66,782 | Common Stock |
| Mineralys Therapeutics Inc | Jon Congleton | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 14.51 per share. | 11 Jul 2025 | 15,884 | 846,405 | - | 14.5 | 230,431 | Common Stock |
| Mineralys Therapeutics Inc | Jon Congleton | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 12.19 per share. | 11 Apr 2025 | 15,319 | 862,289 | - | 12.2 | 186,803 | Common Stock |
| Mineralys Therapeutics Inc | Jon Congleton | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 570,000 | 570,000 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | Jon Congleton | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 9.06 per share. | 13 Jan 2025 | 18,333 | 877,608 | - | 9.1 | 166,082 | Common Stock |
| Mineralys Therapeutics Inc | Jon Congleton | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 13.52 per share. | 11 Oct 2024 | 15,271 | 895,941 | - | 13.5 | 206,433 | Common Stock |
| Mineralys Therapeutics Inc | Jon Congleton | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 13.34 per share. | 11 Jul 2024 | 15,746 | 911,212 | - | 13.3 | 210,075 | Common Stock |
| Mineralys Therapeutics Inc | Jon Congleton | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 12.25 per share. | 17 Jun 2024 | 17,766 | 958,505 | - | 12.3 | 217,712 | Common Stock |
| Mineralys Therapeutics Inc | Jon Congleton | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 11.99 per share. | 17 Jun 2024 | 16,607 | 941,898 | - | 12.0 | 199,073 | Common Stock |
| Mineralys Therapeutics Inc | Jon Congleton | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 11.73 per share. | 17 Jun 2024 | 14,940 | 926,958 | - | 11.7 | 175,237 | Common Stock |
| Mineralys Therapeutics Inc | Jon Congleton | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 12.74 per share. | 12 Jun 2024 | 39,961 | 992,500 | - | 12.7 | 509,027 | Common Stock |
| Mineralys Therapeutics Inc | Jon Congleton | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 12.77 per share. | 12 Jun 2024 | 16,607 | 1,032,461 | - | 12.8 | 212,013 | Common Stock |
| Mineralys Therapeutics Inc | Jon Congleton | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 12.52 per share. | 12 Jun 2024 | 16,229 | 976,271 | - | 12.5 | 203,163 | Common Stock |
| Mineralys Therapeutics Inc | Congleton Jon | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 425,000 | 425,000 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | Jon Congleton | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 12.10 per share. | 17 Aug 2023 | 2,250 | 1,042,568 | - | 12.1 | 27,225 | Common Stock |
| Mineralys Therapeutics Inc | Jon Congleton | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 12.89 per share. | 11 Aug 2023 | 2,000 | 1,040,318 | - | 12.9 | 25,780 | Common Stock |
| Mineralys Therapeutics Inc | Jon Congleton | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2023 | 99,800 | 99,800 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | Jon Congleton | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 250,046 | 250,046 | - | - | Stock Option |